04:55 PM EDT, 08/15/2024 (MT Newswires) -- Incyte ( INCY ) said Thursday that its cancer drug Monjuvi met the primary goal of phase 3 study by showing progression-free survival in patients with relapsed or refractory follicular lymphoma.

Incyte ( INCY ) was evaluating Monjuvi, or tafasitamab, in combination with lenalidomide and rituximab in the study, according to the company.

The company plans to file a supplemental biologics application for the drug by year-end to treat patients with follicular lymphoma who have failed at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy.

Price: 61.35, Change: -0.33, Percent Change: -0.54